Business Context and Reporting Period
This Form 13F-HR filing is submitted by Takeda Pharmaceutical Co Ltd, an institutional investment manager, for the quarter ended September 30, 2024. The report discloses the manager's holdings in U.S. equity securities. The filing includes one other included manager: Takeda Vaccines, Inc.
Key Financial Metrics
As a Form 13F filing, this document reports portfolio holdings rather than the operating financial performance of Takeda Pharmaceutical Co Ltd itself. Key metrics from the filing include:
- Total Value of Reported Holdings: $37,950,196
- Total Number of Holdings Entries: 12
- Number of Other Included Managers: 1
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for Takeda Pharmaceutical Co Ltd.
Material Changes
The filing text does not provide comparative data for the prior period (June 30, 2024) or detail specific material changes in holdings, such as purchases or sales, within the summary section provided.
Guidance, Outlook, and Risks
This filing type does not contain management commentary, forward-looking guidance, risk factors, or contingencies regarding the company's business operations. It is a regulatory disclosure of securities ownership.
Investor Verification Checklist
- Verify the total value of reported holdings ($37,950,196) against the full schedule of holdings to understand the portfolio composition.
- Confirm the identity of the included manager, Takeda Vaccines, Inc., and review its separate filings if necessary.
- Note that this document does not reflect Takeda Pharmaceutical Co Ltd's own financial health or stock performance.
- Check the signature date (February 13, 2025) to ensure the filing was submitted within the regulatory deadline.